Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
This article was originally published in The Pink Sheet Daily
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
You may also be interested in...
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.